Ann Pediatr Endocrinol Metab.  2022 Dec;27(4):245-246. 10.6065/apem.2222019edi04.

Commentary on “Remission in pediatric Graves’ disease treated with antithyroid drug and the risk factors associated with relapse”

• Kim JH

• KMID: 2537235
• DOI: http://doi.org/10.6065/apem.2222019edi04

Reference

References

1. Lee HG, Yang EM, Kim CJ. Efficacy and adverse events related to the initial dose of methimazole in children and adolescents with Graves' disease. Ann Pediatr Endocrinol Metab. 2021; 26:199–204.

2. van Lieshout JM, Mooij CF, van Trotsenburg ASP, Zwaveling-Soonawala N. Methimazole-induced remission rates in pediatric Graves' disease: a systematic review. Eur J Endocrinol. 2021; 185:219–29.

3. Mooij CF, Cheetham TD, Verburg FA, Eckstein A, Pearce SH, Léger J, et al. 2022 European Thyroid Association Guideline for the management of pediatric Graves' disease. Eur Thyroid J. 2022; 11:e210073.

4. Bayramoğlu E, Elmaogulları S, Sagsak E, Aycan Z. Evaluation of long-term follow-up and methimazole therapy outcomes of pediatric Graves' disease: a singlecenter experience. J Pediatr Endocrinol Metab. 2019; 32:341–6.

5. Kaguelidou F, Alberti C, Castanet M, Guitteny MA, Czernichow P, Léger J. Predictors of autoimmune hyperthyroidism relapse in children after discontinuation of antithyroid drug treatment. J Clin Endocrinol Metab. 2008; 93:3817–26.

6. Glaser NS, Styne DM. Predictors of early remission of hyperthyroidism in children. J Clin Endocrinol Metab. 1997; 82:1719–26.

7. Rho JG, Kum CD, Seo YJ, Shim YS, Lee HS, Hwang JS. Long-term outcomes of Graves' disease in children and adolescents receiving antithyroid drugs. Ann Pediatr Endocrinol Metab. 2021; 26:266–71.

8. Wong TWC, Shirley WMY. Remission in paediatric Graves’ disease treated with antithyroid drug and the risk factors associated with relapse. Ann Pediatr Endocrinol Metab. 2022; 27:308–14.